HONEYWELL RUNWAY SAFETY TECHNOLOGY SELECTED BY SOUTHWEST AIRLINES FOR FLEETWIDE INSTALLATION
PARIS, June 16, 2025 /PRNewswire/ -- Honeywell (NASDAQ: HON) today announced that Southwest Airlines (NYSE: LUV) is in the process of activating its entire Boeing 737 aircraft fleet with SmartRunway and SmartLanding software designed to increase runway safety. This capability is enabled via the Honeywell Enhanced Ground Proximity Warning System (EGPWS) already on Southwest aircraft, and more than 700 aircraft have been activated to date.
SmartRunway and SmartLanding helps increase flight crew situational awareness during taxi, take-off and landing with aural and visual alerts and promotes stabilized approaches. It proactively notifies pilots when they are moving too fast, fly too high or are directed toward the wrong runway, helping to break the chain of events that may lead to runway accidents. SmartRunway and SmartLanding is certified for most Airbus and Boeing aircraft, as well as numerous business aviation platforms.
'Today's pilots face increasing challenges including unpredictable weather and dense traffic in limited airspace, forcing them to make split-second decisions during takeoff and landing. Fortunately, as the challenges evolve, so does the technology that provides the information they need in real time,' said Jim Currier, president and CEO of Honeywell Aerospace Technologies. 'Southwest is continuing to put pilots and passengers first by investing in SmartRunway and SmartLanding software across its fleet.'
Honeywell's next-generation runway safety technology, Surface Alerts (SURF-A), is now being tested and is expected to be certified on commercial air transport aircraft in 2026 pending regulatory approvals. SURF-A is a groundbreaking cockpit alerting software that uses GPS data, Automatic Dependent Surveillance-Broadcast equipment and advanced analytics to provide pilots with direct aural and visual alerts of potential runway traffic. Like SmartRunway and SmartLanding, SURF-A is enabled via Honeywell's EGPWS.
This agreement furthers Honeywell's long-standing partnership with Southwest, the world's largest 737 platform operator. In 2015, Southwest selected Honeywell flight-deck systems for its 240-unit order of 737 MAX airliners, adding to its existing fleet of 737 Next Generation models flying with Honeywell cockpit avionics. Southwest was also the first airline to incorporate Honeywell's Integrated Multi-Mode Receiver technology into its fleet.
'Safety is at the heart of everything we do at Southwest,' said Andrew Watterson, chief operating officer at Southwest Airlines. 'Honeywell's SmartRunway and SmartLanding software will provide our pilots with enhanced situational awareness to ensure the highest level of safety while operating on runways throughout the network.'
About Honeywell
Products and services from Honeywell Aerospace Technologies are found on virtually every commercial, defense and space aircraft, and in many terrestrial systems. The Aerospace Technologies business unit builds aircraft engines, cockpit and cabin electronics, wireless connectivity systems, mechanical components, power systems, and more. Its hardware and software solutions create more fuel-efficient aircraft, more direct and on-time flights and safer skies and airports. For more information, visit aerospace.honeywell.com or follow Honeywell Aerospace Technologies on LinkedIn.
Honeywell is an integrated operating company serving a broad range of industries and geographies around the world. Our business is aligned with three powerful megatrends – automation, the future of aviation and energy transition – underpinned by our Honeywell Accelerator operating system and Honeywell Forge IoT platform. As a trusted partner, we help organizations solve the world's toughest, most complex challenges, providing actionable solutions and innovations through our Aerospace Technologies, Industrial Automation, Building Automation and Energy and Sustainability Solutions business segments that help make the world smarter and safer, as well as more secure and sustainable. For more news and information on Honeywell, please visit www.honeywell.com/newsroom.
Contact:
Media
Adam Kress
602-760-6252
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/honeywell-runway-safety-technology-selected-by-southwest-airlines-for-fleetwide-installation-302479393.html
SOURCE Honeywell International Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
ONWARD Medical Builds Commercial Momentum for the ARC-EX System and Reinforces its Brain-Computer Interface Leadership in Q1 2025
EINDHOVEN, the Netherlands, June 17, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces its Q1 2025 business update and year-to-date highlights: Commercial traction: Following FDA market authorization, the Company met its Q1 objective for the limited initial phase of its US launch of the ARC-EX® System, hiring, training and deploying a field organization, establishing a sales and service process, building a roster of reference clinics, and selling ten systems. Technology advancement: The Company's investigational ARC-IM® and ARC-BCI® platforms reached new milestones with the 4th and 5th successful BCI implants to restore thought-driven movement, and the first human implant of its investigational ARC-IM Lumbar Lead, which is designed to help restore mobility. Scientific leadership: Further expanding the body of clinical evidence supporting the ARC-EX System, Pathfinder2 study results published in Neuromodulation: Technology at Neural Interface showed that sustained access to ARC-EX Therapy can continue to drive functional improvements. Participants continued to make gains after one year of treatment. Financial highlights: The Company established a sponsored Level 1 American Depositary Receipt ("ADR") program to facilitate US investor trading and participation in its growth. "Our Q1 achievements reflect ONWARD's successful transition to a commercial organization that delivers breakthrough therapies to people with spinal cord injuries," said Dave Marver, Chief Executive Officer of ONWARD Medical. "The initial demand for our ARC-EX System and strong positive feedback we've received from users gives us confidence we can deliver against expectations in 2025.' Commercial traction ONWARD met its Q1 objective for the limited initial phase of its US launch of the ARC-EX System, hiring, training and deploying a field organization, establishing a sales and service process, building a roster of reference clinics, and selling ten systems. Strong early demand and positive feedback from users suggest the Company expects to meet its 1H sales target of approximately 30 systems and deliver a strong 2025. The Company also secured access to prominent US government online procurement platforms, enabling Veterans Affairs (VA) and other US government buyers to purchase the ARC-EX System. Technology advancement ARC-IM System In the first quarter, ONWARD announced the first human implant of its ARC-IM Lumbar Lead. The new lead is designed for placement in the lumbar region of the spinal cord, the optimal location for therapies targeting restoration of standing, stepping, and lower limb mobility. The Company's ARC-IM Thoracic Lead has been used in humans since early 2023. The Company also announced two new grants to support early clinical feasibility studies using its ARC-IM System to help people with Parkinson's disease. The Michael J. Fox Foundation for Parkinson's Research (MJFF) awarded the Company's research partner .NeuroRestore a USD 1M grant to explore how the ARC-IM System can address mobility challenges in Parkinson's disease. The US Department of Defense awarded a USD 1.5M grant to ONWARD and .NeuroRestore to support a clinical feasibility study to explore how the ARC-IM System can address blood pressure instability in Parkinson's disease. The Company continues to prepare for the initiation of Empower BP, a global pivotal study to assess the safety and efficacy of the ARC-IM System to address blood pressure instability after SCI. Commencement of the study is pending Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA). ARC-BCI System In June, ONWARD announced the 4th and 5th successful implants of its ARC-BCI technology in two additional individuals. These achievements further reinforce ONWARD's leadership in developing BCI-enabled movement solutions for people with SCI. Both procedures were performed at Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland, under the direction of Jocelyne Bloch, MD, Chief of Neurosurgery. The Company's innovations with BCI technology were featured on CBS 60 Minutes with Anderson Cooper, one of the most respected and longest-running US news programs. The segment highlighted the experience of study participants who received this breakthrough therapy. A companion segment, 60 Minutes Overtime, highlighted the Company's other advancements in SCI and Parkinson's disease. Scientific leadership In the first quarter, ONWARD announced the publication of positive results from the investigator-sponsored Pathfinder2 Study in Neuromodulation: Technology at Neural Interface. This peer-reviewed publication details findings from a one-year trial demonstrating that ARC-EX Therapy combined with activity-based rehabilitation delivered significant functional improvements when administered to people with SCI in community-based rehabilitation centers. Participants experienced gains in upper body strength, trunk control, and balance at one year of treatment, indicating no plateau in therapeutic benefit1. Financial highlights As part of the phased launch of the ARC-EX System in the US, the Company reported EUR 0.4M in revenue. The quarter ended with net cash of EUR 50.5M, in line with expectations. Facilitating greater access for US investors, in April the Company established a sponsored Level 1 American Depositary Receipt ("ADR") program through the Bank of New York Mellon ("BNY"). The ADRs trade on the OTCQX® Best Market under the symbol: ONWRY. Outlook Strong early demand for the ARC-EX System and positive feedback from initial users suggest ONWARD expects to meet its 1H sales target of approximately 30 systems and deliver a strong 2025 in line with expectations. The Company anticipates FDA clearance to market the ARC-EX System for home use. It also anticipates CE Mark authorization so it can begin marketing the device in Europe. The Company further expects to commence its Empower BP global pivotal study for the ARC-IM System. It also plans additional implants of its ARC-IM System and ARC-BCI to explore additional indications in SCI and Parkinson's disease. Webcast details ONWARD will hold a webcast today at 2:00PM CET / 08:00AM EST, hosted by CEO Dave Marver. To join the session, please register using this link. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury (SCI) and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The Company's ARC-EX System is cleared for commercial sale in the US. In addition, the Company is developing an investigational implantable system called ARC-IM with and without an implanted brain-computer interface (BCI). Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). For more information, visit and connect with us on LinkedIn. To be kept informed about the Company's technologies, research studies, and the availability of therapies in your area, please complete this webform. For Media Inquiries: Sébastien Cros, VP communications media@ For Investor Inquiries: investors@ Disclaimer Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited. 1ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive). Other Investigational Products: All other ONWARD Medical devices and therapies including ARC-IM and ARC-BCI are investigational and not available for commercial use.
Yahoo
17 minutes ago
- Yahoo
FirstFarms' top management is in position
The board has recruited internally for the CEO position. After a thorough assessment, the Board of Directors of FirstFarms A/S has appointed Søren Bredvig and Michael Hyldgaard as permanent Co-CEO's of FirstFarms with immediate effect. Søren Bredvig and Michael Hyldgaard have served as interim Co-CEO's since 1 May 2025. Both have, for a number of years in their respective roles as COO and CFO, demonstrated strong commitment, solid business understanding, and excellent leadership and collaboration skills. They will continue in their roles as COO and CFO while also taking on the overall responsibility for leading and operating the company. Chairman of the Board Asbjørn Børsting says:"We are pleased that it has been possible to recruit internally for such an important position. Søren and Michael are, with their deep knowledge of operations, organisation and economics, the right people to ensure the necessary continuity and continued operation of the company. Including not least the extensive reconstruction of milk production, which was hit by foot and mouth disease in the spring." In a joint statement, Søren Bredvig and Michael Hyldgaard say: "We thank the Board of Directors for the trust shown to us and look forward to continuing the close collaboration. We also look forward to continuing the collaboration with all our talented colleagues. Together, we will show that we are among the best operated companies in Europe, and we will build on the strong foundation that has been created in recent years." Best regards,FirstFarms A/S For further information:Please visit our website or by contacting chairman Asbjørn Børsting, Co-CEO's Søren Bredvig and Michael Hyldgaard on phone +45 75 86 87 87. About FirstFarms:FirstFarms is a Danish stock exchange listed company. We operate FirstFarms with responsibility for the surrounding communities, and we deliver highest quality which is primarily sold locally. We act on new opportunities, that create value for our investors and for the surroundings. Every day, we work on creating a more sustainable company. Attachment (24) FirstFarms top management is in positionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
18 minutes ago
- Wall Street Journal
Informa Maintains Guidance After Growth in Key Segments
Informa backed its full-year guidance after it reported higher underlying revenue for the five first months of the year, reflecting continued growth in its key divisions. The events and academic-publishing group said Tuesday that underlying revenue rose 9.3% in the first five months of the year, driven by growth in its business-to-business live events segment and academic-markets division.
